DB17630InvestigationalProtein Based Therapies
AGT-182 is an investigational enzyme replacement therapy engineered by the fusion of the iduronate-2-sulfatase (IDS) enzyme and a human insulin receptor monoclonal antibody.
- Also known as
- HIRMAb-IDS · Recombinant human insulin receptor monoclonal antibody-fused iduronate 2-sulfatase
- Code names
- AGT-182 · SHP-631 · TAK-531
What you can answer from here — as of April 23, 2025
Which companies are running trials of AGT-182, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account